Fennec Pharmaceuticals Financials - Benzinga

Fennec Pharmaceuticals Inc

FENCNASDAQ

Trade with Public

Trade with Public

$11.40

0.110.97%

At close: Aug 24, 5:00 PM EST

$11.35

-0.05-0.44%

After Hours: 7:24 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Fennec Pharmaceuticals Financials

Fennec Pharmaceuticals (FENC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Fennec Pharmaceuticals Q2 EPS $0.05 Beats $0.02 Estimate, Sales $17.874M Beat $16.095M Estimate

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 145.45 percent increase over losses of $(0.11) per share

Benzinga Newsdesk

Earnings Scheduled For May 14, 2026

Benzinga Insights

PRO
Fennec Pharmaceuticals Q4 GAAP EPS $(0.17) Misses $0.04 Estimate, Sales $13.777M Miss $13.993M Estimate

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $0.04 by 572.22 percent. This is a 183.33 percent decrease over losses of $(0.06) per

Benzinga Newsdesk

Earnings Scheduled For March 24, 2026

Benzinga Insights

Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Fennec Pharmaceuticals (FENC) to release Q4 earnings on March 24. Analysts expect EPS of $0.04 and revenue of $14.73 million. Stock gained 1.8% on Monday.

Avi Kapoor

PRO
Fennec Pharmaceuticals Q3 EPS $(0.02), Inline, Sales $12.462M Beat $11.257M Estimate

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 90.48 percent increase over losses of $(0.21) per share from the same period last

Benzinga Newsdesk